NCT00299494 2018-03-08Study Evaluating Inotuzumab Ozogamicin [CMC-544] Administered In Combination With Rituximab In Subjects With Non-Hodgkin's Lymphoma (NHL)PfizerPhase 1/2 Completed119 enrolled 60 charts